Introduction  

Los Angeles County has experienced a significant shift in opioid-related overdose patterns over the past two decades. In the early 2000s, overdose deaths were primarily associated with prescription opioid medications. In the following years, heroin became more prevalent. Today, illicitly manufactured fentanyl is the dominant driver of opioid-related mortality.

National data from the Centers for Disease Control and Prevention indicate that synthetic opioids, primarily fentanyl, are now involved in the majority of opioid overdose deaths in the United States. Los Angeles County reflects this national trend, with local public health authorities reporting increasing fentanyl involvement in toxicology findings.

Accordingly, understanding the evolving relationship between prescription opioid use and illicit fentanyl exposure is essential. Over the past decade, prescribing practices in California have changed substantially in response to regulatory guidance and public health initiatives. Nevertheless, despite these reductions in prescription volume, individuals with untreated opioid use disorder remain vulnerable within an increasingly dangerous and unpredictable drug supply.

In this context, it becomes important to examine how prescription opioids historically influenced earlier phases of the epidemic. At the same time, it is equally critical to understand how fentanyl differs pharmacologically and clinically from traditional opioids. Therefore, this article explores the transition from prescription-driven misuse to illicit synthetic opioid exposure and reviews the prevention and treatment strategies that are currently most effective in Los Angeles County.

Understanding Prescription Opioids and Fentanyl in Los Angeles

Common Types of Prescription Opioids

Prescription opioids are controlled medications used to manage moderate to severe pain. Common agents include:

• Oxycodone
• Hydrocodone
• Morphine
• Codeine
• Hydromorphone

These medications are regulated under the Controlled Substances Act and require physician oversight. When used appropriately for short-term or carefully monitored chronic pain, they can be effective.

However, prolonged use may lead to:

• Physiologic dependence
• Tolerance (requiring higher doses for the same effect)
• Increased risk of opioid use disorder

In response to rising overdose rates during the early 2000s, California strengthened prescribing regulations and implemented Prescription Drug Monitoring Programs (PDMPs) to track controlled substance prescriptions.

As prescribing rates declined, illicit opioid markets expanded.

What Is Fentanyl?

Fentanyl is a synthetic opioid that is significantly more potent than morphine or oxycodone. Pharmaceutical fentanyl is used in hospitals for severe pain, including cancer-related pain and surgical anesthesia.

The current crisis in Los Angeles County is primarily driven by illicitly manufactured fentanyl. According to the Drug Enforcement Administration, non-pharmaceutical fentanyl is frequently mixed with:

• Heroin
• Cocaine
• Methamphetamine
• Counterfeit prescription pills

Key differences between fentanyl and most prescription opioids include:

• Rapid onset of respiratory depression
• Narrow margin between therapeutic and lethal dose
• Increased overdose risk even in opioid-experienced individuals
• High unpredictability in illicit formulations

These characteristics make fentanyl exposure particularly dangerous, especially when individuals are unaware it is present.

 

Historical Opioid Trends in Los Angeles County

Evolution of Prescribing Practices

During the early 2000s, opioid prescribing increased nationally. Greater attention to pain management contributed to expanded opioid availability.

Over time, concerns about misuse, diversion, and overdose led to:

• CDC prescribing guidance
• California PDMP implementation
• Tighter regulatory oversight
• Reduced prescription volumes

While prescription rates declined, opioid use disorder did not disappear. Some individuals with dependence transitioned to heroin. As heroin became contaminated with fentanyl, overdose risk increased further.

Transition from Prescription Opioids to Illicit Fentanyl

Federal public health research describes a three-wave pattern:

1. Prescription opioid misuse
2. Increased heroin use
3. Emergence of fentanyl in the illicit supply

In Los Angeles County, fentanyl increasingly replaced heroin in overdose toxicology reports.

Importantly, most fentanyl-related deaths today are linked to illicit supply rather than active medical prescriptions. Many individuals who die from fentanyl overdose did not obtain the substance through legitimate healthcare channels.

The current epidemic is driven primarily by an unpredictable and contaminated drug market.

 

How Prescription Opioids May Influence Fentanyl Overdose Risk

Pathways of Risk

Public health studies suggest that prescription opioid exposure may contribute to later vulnerability in certain circumstances:

• Long-term opioid use without tapering
• Untreated opioid use disorder
• Abrupt discontinuation without medical support
• Chronic pain without adequate multidisciplinary care

If opioid use disorder is not treated, individuals may seek opioids outside medical settings, increasing exposure to fentanyl-contaminated products.

However, it is essential to emphasize that most fentanyl-related deaths in Los Angeles are now associated with illicit drug markets, not ongoing prescribed opioid therapy.

 

Risk Factors for Transition to Illicit Opioids

Risk factors include:

• Untreated opioid use disorder
• Co-occurring mental health disorders
• Housing instability
• Limited access to addiction treatment
• Chronic pain with inadequate support

The Substance Abuse and Mental Health Services Administration emphasizes that medication-assisted treatment significantly reduces mortality and relapse risk.

Access to structured medical treatment reduces the likelihood of exposure to illicit fentanyl.

 

Demographics Most Affected in Los Angeles County

Age and Socioeconomic Factors

Los Angeles County data indicate that fentanyl-related deaths have increased among:

• Young adults
• Latino communities
• Economically vulnerable populations

Barriers to care, including language access, insurance coverage, and stigma, can influence treatment access.

National CDC data show widening demographic impact across racial and ethnic groups, underscoring the broad reach of synthetic opioids.

 

Geographic Hotspots

Areas with higher rates of poverty, housing instability, and limited healthcare access may, therefore, experience a disproportionately greater overdose burden. In particular, social determinants of health can intensify vulnerability to untreated opioid use disorder and delayed medical intervention.

Accordingly, local surveillance data enable public health authorities to more precisely target resources, including:

• Naloxone distribution
• Expansion of treatment services
• Community outreach initiatives

By directing interventions to the communities most affected, public health systems can respond more strategically. Ultimately, targeted, using local public health data interventions improve outcomes and reduce overdose deaths that could be avoided.

 

Public Health Response in Los Angeles

In response to evolving overdose trends, the Los Angeles County Department of Public Health has issued formal alerts highlighting several urgent concerns, including:

• Increased fentanyl contamination within the illicit drug supply
• Rising exposure among adolescents and young adults
• The critical importance of naloxone availability
• The continued need to expand access to evidence-based treatment services

In addition to these alerts, public health authorities have implemented multiple community-level prevention strategies. These efforts are designed not only to reduce overdose risk but also to improve early intervention and treatment engagement.

Current community prevention initiatives include:

• School-based fentanyl education programs to improve awareness among youth
• Expanded naloxone distribution programs across pharmacies and community organizations
• Harm reduction services aimed at reducing immediate overdose risk
• Broader access to medication-assisted treatment for opioid use disorder

Together, these coordinated public health measures aim to reduce overdose mortality, improve treatment access, and strengthen community-wide prevention efforts.

Evidence consistently demonstrates that MAT reduces overdose mortality compared to no treatment.

 

Physician-Led Telehealth Treatment for Opioid Use Disorder in Los Angeles County

DevotedDOc provides physician-led telehealth treatment for opioid use disorder throughout California, including Los Angeles County.

Comprehensive Clinical Evaluation

First, all patients undergo a comprehensive evaluation by a licensed physician. During this assessment, the physician applies DSM-5 criteria to determine whether opioid use disorder is present and to evaluate severity.

If clinically appropriate, the physician may then initiate buprenorphine/naloxone (Suboxone) as part of a carefully individualized treatment plan. Importantly, medication initiation follows a structured protocol designed to prioritize safety and stabilization.

Ongoing care includes:

• Supervised medication induction, particularly during the early phase of treatment
• Regular dose adjustments based on clinical response
• Continuous monitoring for safety, adherence, and treatment effectiveness
• Evaluation and management of co-occurring medical or psychiatric conditions

Through this structured and closely monitored approach, treatment remains both evidence-based and responsive to each patient’s evolving clinical needs.

 

Evidence-Based Approach

Treatment protocols align with national guidance from:

• Centers for Disease Control and Prevention
• Substance Abuse and Mental Health Services Administration
• National Institute on Drug Abuse

The focus is long-term stabilization and overdose risk reduction.

 

Telehealth Accessibility and Privacy

Care is delivered via secure, HIPAA-compliant telemedicine platforms. As a result, accessibility improves for individuals in Los Angeles County who face barriers such as:

• Transportation limitations
• Work schedule constraints
• Concerns related to stigma

In addition, telehealth supports continuity of care by allowing structured follow-up visits without requiring in-person travel. At the same time, patient confidentiality is maintained through secure, compliant technology.

Furthermore, DevotedDOc emphasizes structured physician oversight rather than one-time prescription access. Instead, physicians individualize each treatment plan, monitor patients closely, and ensure full compliance with both California and federal regulations. Consequently, patients receive ongoing medical supervision designed to support safety, stability, and long-term outcomes.

 

Conclusion

The relationship between prescription opioids and fentanyl overdoses in Los Angeles County is complex and has evolved over time.

Although historical prescribing patterns contributed to earlier waves of opioid misuse, illicitly manufactured fentanyl now drives the current crisis as it circulates through unpredictable and highly contaminated drug markets. As a result, today’s overdose risk stems less from legitimate medical prescribing and more from direct exposure to unregulated synthetic opioids.

Therefore, reducing overdose deaths in Los Angeles requires a comprehensive and coordinated response that includes:

• Expanded access to medication-assisted treatment
• Ongoing public education initiatives
• Evidence-based harm reduction strategies
• Physician-led, evidence-based clinical care

Moreover, early medical evaluation and structured treatment significantly reduce overdose risk, particularly in the fentanyl era where tolerance changes and unpredictable drug potency increase vulnerability.

If you or someone you care about is living with opioid use disorder, schedule a confidential telehealth evaluation with a licensed DevotedDOc physician to discuss evidence-based treatment options and structured medication-assisted care.

Evidence-based care saves lives.

– DevotedDOc
Physician-Led Virtual Addiction & Reentry Care
Serving Florida,Georgia, New Mexico, Oklahoma, California, Texas and beyond.

Medically Reviewed By

Dr. Keith Baker, MD

Addiction Medicine | Medical Toxicology | Emergency Medicine

References

1. Centers for Disease Control and Prevention. Drug overdose deaths in the United States. National Center for Health Statistics. Updated 2024. Accessed March 8, 2026. https://www.cdc.gov/drugoverdose/deaths/index.html
2. Centers for Disease Control and Prevention. Understanding the opioid overdose epidemic. Updated 2024. Accessed March 8, 2026. https://www.cdc.gov/drugoverdose/epidemic/index.html
3. Centers for Disease Control and Prevention. CDC clinical practice guideline for prescribing opioids for pain — United States. Updated 2022. Accessed March 8, 2026. https://www.cdc.gov/opioids/providers/prescribing/guideline.html
4. Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder (Treatment Improvement Protocol 63). Updated 2021. Accessed March 8, 2026. https://store.samhsa.gov/product/TIP-63
5. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States. Updated 2024. Accessed March 8, 2026. https://www.samhsa.gov/data
6. National Institute on Drug Abuse. Fentanyl drugfacts. Updated 2024. Accessed March 8, 2026. https://nida.nih.gov/publications/drugfacts/fentanyl
7. National Institute on Drug Abuse. Prescription opioids drugfacts. Updated 2024. Accessed March 8, 2026. https://nida.nih.gov/publications/drugfacts/prescription-opioids
8. Drug Enforcement Administration. National drug threat assessment. Updated 2024. Accessed March 8, 2026. https://www.dea.gov/resources/drug-threat-assessment
9. Los Angeles County Department of Public Health. Substance abuse prevention and control data dashboard. Updated 2025. Accessed March 8, 2026. http://publichealth.lacounty.gov/sapc
10. California Department of Public Health. California opioid surveillance dashboard. Updated 2025. Accessed March 8, 2026. https://skylab.cdph.ca.gov/ODdash/
11. Centers for Disease Control and Prevention. Synthetic opioids data and surveillance. Updated 2024. Accessed March 8, 2026. https://www.cdc.gov/drugoverdose/data/synthetic/index.html
12. Controlled Substances Act, 21 USC § 801 et seq. US Drug Enforcement Administration. Accessed March 8, 2026. https://www.deadiversion.usdoj.gov/21cfr/21usc/